“Due to the Company’s strong financial backing
Post# of 72440
Posted On: 08/12/2013 3:26:12 AM
“Due to the Company’s strong financial backing from our $10 million equity line from Aspire Capital, and further progress in our clinical trials, we are intending to move to a senior exchange,” commented Leo Ehrlich, CEO.
I take it the further progress in our clinical trials is somewhere between good and out-of-this-world fantastic. Anything less would make an intention to up-list unfounded. Sounds good to me!
I take it the further progress in our clinical trials is somewhere between good and out-of-this-world fantastic. Anything less would make an intention to up-list unfounded. Sounds good to me!
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼